Log in to save to my catalogue

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell car...

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell car...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751214391

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial

About this item

Full title

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2015-12, Vol.16 (16), p.1630-1638

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background The combination of nedaplatin, a cisplatin derivative, and docetaxel showed promising activity for advanced squamous cell lung carcinoma in a previous phase 1–2 study. We compared nedaplatin plus docetaxel with cisplatin plus docetaxel in patients with previously untreated advanced or relapsed squamous cell lung carcinoma to dete...

Alternative Titles

Full title

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1751214391

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751214391

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(15)00305-8

How to access this item